Related Experiment Video
Updated: Jun 24, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Understanding the Impact of Salvage Radiation on the Long-Term Natural History of Biochemically Recurrent Prostate
Spyridon P Basourakos1, Stephen A Boorjian1, Phillip J Schulte2
1Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
Purpose:
The natural history of biochemical recurrence (BCR) after radical prostatectomy (RP) remains understudied, with limited long-term data from large cohorts inclusive of both salvage radiotherapy (SRT)-treated and untreated patients. Herein, we sought to evaluate the outcomes of patients with BCR and the impact of SRT on disease progression.
Materials And Methods:
Patients undergoing RP who developed BCR (PSA ≥ 0.20 ng/mL) were included. Patients with BCR treated with SRT were compared to untreated patients using risk-set matching with time-dependent propensity scores. The primary outcome was metastases, analyzed using Kaplan-Meier and Cox models. The number needed to treat (NNT) with SRT to prevent progression was derived at 5 and 15 years.
Results:
Among 6881 patients with BCR, 2109 received SRT. At a median follow-up of 10.2 years, 1147 patients developed metastases. The median PSA at the time of SRT was 0.50 ng/mL. After 1:1 propensity score matching (2109 patients per cohort), SRT significantly reduced the risk of metastases at 5 (12.7% vs. 19.3%, p < 0.0001) and 15 years (28.6% vs. 31.5%, p < 0.001). On multivariable analysis, SRT independently reduced metastasis risk (HR 0.75, 95% CI 0.63-0.90, p = 0.002), translating to NNT of 23 and 15 at 5 and 15 years, respectively. Interaction analyses between SRT and nodal status (p = 0.04) showed greater metastasis risk reduction in pN+ (HR 0.41, 95% CI 0.22-0.77, p = 0.005) compared to pN- disease (HR 0.81, 95% CI 0.67-0.97, p = 0.02).
Conclusions:
Most patients with BCR post-RP do not progress to metastasis. For those who do progress, SRT inarguably improves the oncologic outcomes in the BCR setting. However, careful patient selection and shared decision making should be encouraged in order to limit overtreatment and side effects.
